{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000128","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.915567+00:00","generated_at":"2026-05-17T15:35:43.465052+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Immunovant Q1 net loss $120.6M; initiates two registrational trials for IMVT-1402","bullets":["Cash of $598.9M provides runway through Graves' disease readout expected in 2027.","Net loss $120.6M ($0.71/share) vs $87.2M ($0.60) in prior-year quarter.","Initiated a second potentially registrational trial of IMVT-1402 in Graves' disease in June 2025.","Initiated a potentially registrational trial of IMVT-1402 in Sjögren's disease in June 2025.","Expects GD remission data from batoclimab proof-of-concept study at ATA meeting in September 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000128","json":"https://secwatch.observer/filing/0001764013-25-000128.json","markdown":"https://secwatch.observer/filing/0001764013-25-000128.md","text":"https://secwatch.observer/filing/0001764013-25-000128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/0001764013-25-000128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/imvt-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:35:43.465052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}